MENU
IMUX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Immunic (IMUX) Ownership - Who owns Immunic?
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more
Industry: #Pharmaceuticals Major
Profile
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
99.99M
P/E Ratio
N/A
Total Cash
59.07M
Projected Growth
N/A
Total Debt
899K
Revenue
N/A
Risk (Beta)
2.06
Dividend Yield
N/A
Total Cash/Share
0.66
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
IMUX
Capitalization
100M
P/E Ratio
N/A
Risk (Beta)
2.06
Dividend Yield
N/A
Total Cash
59.1M
Total Cash/Share
0.66
Total Debt
899K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
41.2M
P/B Ratio
5.43
Cash Flow
N/A
Earnings
-1.23
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
2.71
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-95.68M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-147.12
Shares Held By Institutions
57.6M
Shares Outstanding - Current
90.1M
Total Liabilities
23.5M
Total Volume MTD
N/A
Value
N/A
Gain YTD
11.000
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com